|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
Hepion Pharmaceuticals, Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
(CUSIP Number) |
Chase LoPriore Gravitas Collective Corp., 155 Pompton Ave., Suite 204 Verona, NJ, 07044 (732) 902-4000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
10/06/2026 (Date of Event Which Requires Filing of This Statement) |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Gravitas Collective Corp. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
25,000,000.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
19.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, par value $0.0001 per share |
| (b) | Name of Issuer:
Hepion Pharmaceuticals, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
c/o Hepion Pharmaceuticals, Inc.,, 22 West Street, Verona,
NEW JERSEY
, 07701. |
| Item 2. | Identity and Background |
| (a) | This Statement is being filed on behalf of Gravitas Collective Corp. (the "Reporting Person"). |
| (b) | The business address of the Reporting Person is 155 Pompton Ave., Suite 204, Verona, NJ 07044. |
| (c) | Not applicable. |
| (d) | No |
| (e) | No |
| (f) | The Reporting Person is a New Jersey corporation. |
| Item 3. | Source and Amount of Funds or Other Consideration |
On October 6, 2026, the Reporting Person received 25,000,000 shares Common Stock of the Issuer in exchange for the membership interests of Gravitas Life Sciences, Inc. solely owned by the Reporting Person. | |
| Item 4. | Purpose of Transaction |
The Common Stock owned by the Reporting Person was acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | See response to Item 5(a) on the cover page for the Reporting Person. |
| (b) | See responses to Item 5(b) on the cover page for the Reporting Person. |
| (c) | Not applicable. |
| (d) | Not applicable. |
| (e) | Not applicable. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
Other than as described herein, the Reporting Person does not have any contracts, arrangements, understandings or relationships with respect to the securities of the Issuer. | |
| Item 7. | Material to be Filed as Exhibits. |
None |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|